Pfizer Recalls More Quinapril Due to Potential Carcinogen
The voluntary recall of five lots of the antihypertensive quinapril (Accupril) was prompted by unacceptable levels of N-nitroso-quinapril, a potential carcinogen. Medscape Medical News
The voluntary recall of five lots of the antihypertensive quinapril (Accupril) was prompted by unacceptable levels of N-nitroso-quinapril, a potential carcinogen. Medscape Medical News